Immune Response to Pneumococcal Vaccination in HIV Infected Individuals

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

124 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study. To characterize the immune response to the pneumococcal vaccine in HIV positive individuals and to dissect the most appropriate timing and frequency of vaccination.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pneumonia Vaccine in Aging HIV Positive Individuals

NCT02558751

Pneumococcal Infection

COMPLETED EARLY_PHASE1

Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting

NCT00622843

HIV Infections Streptococcus Pneumoniae

COMPLETED PHASE3

Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects

NCT00706550

HIV Infections

COMPLETED NA

Perturbing of HIV Reservoir With Immune Stimulation

NCT02707692

AIDS HIV

COMPLETED NA

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

NCT05794191

HIV Pneumonia Infections, Pneumococcal

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All potential study candidates will be asked to fill out a questionnaire concerning their medical history and medications. This survey will determine eligibility. If eligible, as part of the experimental protocol the HIV positive participants will agree to be randomized to immediate vs. delayed pneumococcal immunization and 3 blood draws around the time of immunization. The HIV negative control population will agree to immunization with pneumococcal polysaccharide vaccine (PPV), not standard of care for this population, and 3 blood draws around the time of immunization. The investigators will study the effect of pneumococcal vaccination in HIV positive adults. At the present time it is recommended that all HIV positive individuals receive the pneumococcal vaccine at the time of diagnosis with those with cluster of differentiation (CD4) count \<200 to be vaccinated either immediately or alternatively, treated with highly active antiretroviral therapy (HAART) for 6 months followed by PPV. All patients are recommended to be re-vaccinated at 5 years. This is the standard of care. It is however unclear how the HIV positive patients respond to PPV. In the 1st part of the study, Part I, newly diagnosed HIV positive individuals will be recruited. As standard of care, these individuals will receive the pneumococcal vaccine regardless of their participation in this study. Those that agree to participate in the study will be grouped according to their CD4 count: \>500, 200-500 or \<200. Those with a CD4 count \<200 will be randomly assigned to receive the vaccine immediately or to receive HAART for 6 months prior to vaccination, this is in accordance with the present recommendations, either immediate vaccination or giving HAART for 6 months prior to vaccination is considered acceptable.. Thus ALL HIV positive individuals will receive the vaccine as presently recommended. The HIV positive volunteers agree to (experimental part of the protocol):

1. Be randomized to either immediate vaccination vs. 6 months after start of HAART if the CD4 count is \<200
2. Donate blood specimens at 3 different times: day 0, day of vaccination: 2 mL, at day 7, 40 mL and at day 28-42 a one time sample of 2 mL.
3. Have their blood samples subjected to antibody analysis (concentration and functional activity) and antibody gene usage analysis There will be 4 HIV positive groups in this part of the study: CD4\>500, CD4 200-500, CD4 \< 200 immediate vaccination and CD4 \<200, delayed vaccination.

There will be 19 individuals per group. The HIV negative controls in Part I of the study (n=19) who agree to participate will also be vaccinated with the pneumococcal vaccine. This is NOT a vaccine recommended for healthy adults but is NOT contra-indicated.

Thus as part of the experimental procedure for these individuals they will:

1. Receive the FDA approved pneumococcal vaccine
2. Blood samples will be obtained at day 0: 2 mL, day 7 40 mL and day 28-42, one time sample of 2 mL.
3. Blood samples will be analyzed for antibody concentration, functional activity and gene family usage.

In summary, we will study a total of 5 groups in Part I:

Group 1: HIV positive CD4\>500 Group 2: HIV positive CD4 200-500 Group 3: HIV positive CD4 \< 200 immediate vaccination Group 4: HIV positive CD4\<200 delayed (6 months) vaccination Group 5: HIV negative In part II of the study the investigators will evaluate the effect of a second pneumococcal vaccination, which is presently recommended, in HIV positive individuals, to be received 5 years after the first vaccination. Again, only those HIV positive individuals who are due for their second pneumovax will be asked to participate. They will be grouped according to their CD4 counts as CD4 \>500 or CD4 200-500. Thus ALL HIV positive individuals will receive the vaccine as recommended.

The HIV positive volunteers solely agree to;

1. Donate blood specimens at 3 different occasions: day 0, day of vaccination: 2 mL, at day 7, 40 mL and at day 28-42 a one time sample of 2 mL.
2. Have their blood samples subjected to antibody analysis (concentration and functional activity) and antibody gene usage analysis There will be 2 HIV positive groups: CD4\>500 and CD4 count 200-500. There will be 19 individuals per group.

The HIV negative controls in Part II of the study who agree to participate will be recruited from the population of individuals previously vaccinated with pneumovax. They will also be vaccinated for the second time with the pneumococcal vaccine, 5 years after the first vaccination. This is NOT a vaccine recommended for healthy adults but is NOT contra-indicated. Thus as part of the experimental procedure for these individuals they will:

1. Receive the FDA approved pneumococcal vaccine
2. Blood samples will be obtained at day 0: 2 mL, day 7 40 mL and day 28-42 one time sample of 2 mL.
3. Blood samples will be analyzed for antibody concentration, functional activity and gene family usage.

In summary, we will study 3 groups in Part II of the study Group 6: HIV positive CD4\>500, 2nd PPV Group 7: HIV positive CD4 200-500, 2nd PPV Group 8: HIV negative, 2nd PPV.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumococcal Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

healthy controls

healthy individuals, HIV negative, 19-50 yrs if age, immunized with one shot of PPV23 vaccine.

Group Type ACTIVE_COMPARATOR